Synlogic Q1 net loss $15.6M; cash $57.4M; PKU program gets FDA/EMA designations

SYNLOGIC, INC.

2023-Q1 EPS reported -$0.23 revenue$174,000

Net loss of $15.6M ($0.23 per share) vs $15.7M in Q1 2022; revenue flat at $0.2M.
Cash, equivalents and short-term investments $57.4M; runway into H2 2024.
FDA granted Rare Pediatric and Orphan Drug Designations for SYNB1934 in PKU; EMA also granted orphan designation.
Phase 3 trial (Synpheny-3) for SYNB1934 in PKU on track to start H1 2023.
SYNB1353 for HCU advancing to Phase 2; preclinical pipeline progressing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SYNLOGIC, INC. reported first quarter ended March 31, 2023 results: revenue $0.2 million, net income consolidated net loss of $15.6 million, EPS $0.23 per share.

Period: first quarter ended March 31, 2023
Revenue: $0.2 million
Net income: consolidated net loss of $15.6 million
EPS: $0.23 per share
Result: reported results

Exact text from the filing

partnerships Page 1 of 4 First Quarter 2023 Financial Results As of March 31, 2023, Synlogic had cash, cash equivalents and short-term investments of $57.4 million. Revenue was $0.2 million for each of the three months ended March 31, 2023 and March 31, 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SYNLOGIC, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-020786

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.